StockData
Exelixis, Inc. logo

Exelixis, Inc. (EXEL) stock

EXELNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends January 1
Financials through Q3 FY2026, quarter ended Oct 2, 2026Last filing: 10-Q on Oct 29, 2026Score 18/303% above fair value
$68.50+1.40 (+2.09%)

Close on Nov 17, 2026Market cap $16.71BP/E 20.5Yield –

Exelixis price to book ratio

The price-to-book ratio is market cap divided by shareholders' equity.

Exelixis's price to book ratio was 9.5× on Nov 11, 2026, against 5.5× a year earlier. Over the last 5 years it ranged from 2.1× to 9.5×, with a median of 3.3×.

Price to Book Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20269.5×+4.1
2025Dec 31, 20255.4×+1.3
2024Dec 31, 20244.2×+1.0
2023Dec 29, 20233.2×+1.1
2022Dec 30, 20222.1×−0.7
2021Dec 31, 20212.7×−0.6
2020Dec 31, 20203.4×+0.0
2019Dec 31, 20193.3×−18.3
2018Apr 30, 201821.6×−51.1
2017Apr 28, 201772.7×–

More Exelixis figures

See a number that looks wrong?